CL2023000926A1 - Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria - Google Patents
Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditariaInfo
- Publication number
- CL2023000926A1 CL2023000926A1 CL2023000926A CL2023000926A CL2023000926A1 CL 2023000926 A1 CL2023000926 A1 CL 2023000926A1 CL 2023000926 A CL2023000926 A CL 2023000926A CL 2023000926 A CL2023000926 A CL 2023000926A CL 2023000926 A1 CL2023000926 A1 CL 2023000926A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- hereditary hemorrhagic
- hemorrhagic telangiectasia
- akt inhibitors
- allosteric akt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2015536.2A GB2600384A (en) | 2020-09-30 | 2020-09-30 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000926A1 true CL2023000926A1 (es) | 2023-11-03 |
Family
ID=73197201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000926A CL2023000926A1 (es) | 2020-09-30 | 2023-03-29 | Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12466839B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4221713A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7900827B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230080448A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116419924A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021352108B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004885A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192433A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023000926A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2600384A (cg-RX-API-DMAC7.html) |
| IL (1) | IL301466A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002996A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022069552A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| WO2026038045A1 (en) | 2024-08-15 | 2026-02-19 | Almac Discovery Limited | Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| JP2008524339A (ja) | 2004-12-15 | 2008-07-10 | メルク エンド カムパニー インコーポレーテッド | Akt活性のインヒビター |
| WO2006135627A2 (en) | 2005-06-10 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of akt activity |
| CA2656507C (en) | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| EP2120951A4 (en) | 2006-12-06 | 2012-02-15 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| JP2011522047A (ja) | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
| US8207169B2 (en) | 2008-06-03 | 2012-06-26 | Msd K.K. | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D |
| EP2116237A1 (en) | 2008-08-05 | 2009-11-11 | Polichem SA | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| US8957064B2 (en) | 2009-02-13 | 2015-02-17 | Bayer Intellectual Property Gmbh | Fused pyrimidines |
| GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| MX336865B (es) | 2011-04-07 | 2016-02-04 | Bayer Pharma AG | Imidazopiridazinas como inhibidores de quinasa akt. |
| EP3294314A4 (en) | 2015-05-15 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES |
| EP3678666B1 (en) | 2017-09-07 | 2025-07-09 | Augusta University Research Institute, Inc. | Specific akt3 activator and uses thereof |
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
-
2020
- 2020-09-30 GB GB2015536.2A patent/GB2600384A/en not_active Withdrawn
-
2021
- 2021-09-29 KR KR1020237014688A patent/KR20230080448A/ko active Pending
- 2021-09-29 CA CA3192433A patent/CA3192433A1/en active Pending
- 2021-09-29 CN CN202180066598.2A patent/CN116419924A/zh active Pending
- 2021-09-29 JP JP2023519016A patent/JP7900827B2/ja active Active
- 2021-09-29 US US18/247,261 patent/US12466839B2/en active Active
- 2021-09-29 EP EP21789616.6A patent/EP4221713A1/en active Pending
- 2021-09-29 IL IL301466A patent/IL301466A/en unknown
- 2021-09-29 BR BR112023004885A patent/BR112023004885A2/pt unknown
- 2021-09-29 WO PCT/EP2021/076811 patent/WO2022069552A1/en not_active Ceased
- 2021-09-29 AU AU2021352108A patent/AU2021352108B2/en active Active
- 2021-09-29 MX MX2023002996A patent/MX2023002996A/es unknown
-
2023
- 2023-03-29 CL CL2023000926A patent/CL2023000926A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021352108A9 (en) | 2024-05-23 |
| EP4221713A1 (en) | 2023-08-09 |
| MX2023002996A (es) | 2023-05-03 |
| CN116419924A (zh) | 2023-07-11 |
| JP2023543993A (ja) | 2023-10-19 |
| US20240092801A1 (en) | 2024-03-21 |
| CA3192433A1 (en) | 2022-04-07 |
| JP7900827B2 (ja) | 2026-08-05 |
| BR112023004885A2 (pt) | 2023-04-18 |
| GB202015536D0 (en) | 2020-11-11 |
| US12466839B2 (en) | 2025-11-11 |
| AU2021352108B2 (en) | 2026-04-02 |
| AU2021352108A1 (en) | 2023-05-11 |
| WO2022069552A1 (en) | 2022-04-07 |
| KR20230080448A (ko) | 2023-06-07 |
| IL301466A (en) | 2023-05-01 |
| GB2600384A (en) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2026004964A2 (es) | Moduladores de kras | |
| CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| UY38696A (es) | Moduladores de alfa-1 antitripsina | |
| MX2024010399A (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| MX2021002804A (es) | Terapias de combinacion. | |
| DOP2023000145A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2023012725A (es) | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| MX2024008551A (es) | Terapias de combinacion. | |
| CL2019000368A1 (es) | Inhibidores de cdk2/4/6. | |
| PE20200335A1 (es) | Compuestos que inhiben la proteina mcl-1 | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| SV2010003567A (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| DOP2010000191A (es) | Derivados bis-(sulfonilamino) | |
| DOP2009000159A (es) | Inhibidores de la poli(adp-ribosa) polimerasa | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
| CL2007002166A1 (es) | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. | |
| MX2025014135A (es) | Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos | |
| MX2023014466A (es) | Derivados de piridopirimidina útiles como inhibidores de cinasa wee1. | |
| CL2024002623A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2. | |
| UY31860A (es) | Piridinas de tiazolo como inhibidoras de la adn girasa | |
| CL2007002381A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis |